| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220913 | Ophthalmology | 2018 | 12 Pages |
Abstract
Emixustat did not reduce the growth rate of GA in AMD. The most common adverse events were ocular in nature and likely related to the drug's mechanism of action. Data gained from this study over a 2-year period add to the understanding of the natural history of GA and the baseline characteristics affecting the growth rate of GA.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Philip J. MD, PhD, Pravin U. MD, Frank G. MD, Jeffrey S. MD, Joel A. MD, PhD, Roger L. MD, PhD, Karl G. MD, PhD, John M. MS, Jeffrey K. MD, Ryo MD, PhD,